Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Dispatch

Seventh Pandemic Vibrio cholerae O1 Sublineages, Central African Republic

Sebastien Breurec1, Thierry Franck12, Elisabeth Njamkepo, Jean-Robert Mbecko, Jean Rauzier, Hugues Sanke-Waïgana, Guyguy Kamwiziku, Renaud Piarroux, Marie-Laure Quilici3, and François-Xavier Weill3Comments to Author 
Author affiliations: Institut Pasteur de la Guadeloupe, Les Abymes, France (S. Breurec); INSERM Centre d’Investigation Clinique 1424, Pointe-à-Pitre/Les Abymes, France (S. Breurec); Université des Antilles, Pointe-à-Pitre, France (S. Breurec); Institut Pasteur de Bangui, Bangui, Central African Republic (S. Breurec, T. Franck, J.-R. Mbecko); Institut Pasteur, Paris, France (E. Njamkepo, J. Rauzier, M.-L. Quilici, F.-X. Weill); Université de Kinshasa, Kinshasa, Democratic Republic of the Congo (G. Kamwiziku); Assistance Publique-Hôpitaux de Paris, Paris (R. Piarroux)

Main Article

Table 1

Characteristics of the Vibrio cholerae O1 isolates associated with outbreaks of cholera, Central African Republic*

Characteristics
 Outbreak no. 1, 1997 Jun–Oct
 Outbreak no. 2, 1997 Jun–Aug
 Outbreak no. 3, 2011 Sept–Oct
 Outbreak no. 4, 2016 Jul–Dec
No. deaths/no. cases† 88/443 19/113 16/172 20/265
No. isolates 9 6 7 8
7PET sublineage T7 T9 T10 T10
Sequence type 69 69 515 515
ctxB B3 B1 B1 B1
wbeT‡ A03 C19 B01 B01
AMR phenotypes (no. isolates)§
 R1 (8), R2 (1)
 R3 (6)
 R3 (7)
 R3 (8)
AMR determinants
Plasmid IncA/C¶ NT NT NT
VC_0715 WT R169C R169C R169C
VC_A0637 WT Q5Stop Q5Stop Q5Stop
SXT/R391 element NT ICEVchInd5 ICEVchInd5 ICEVchInd5
gyrA WT WT S83I S83I

*7PET, seventh pandemic Vibrio cholerae O1 El Tor; AMR, antimicrobial resistance; NT, not detected; WT, wild type.
†Data from the International Federation of Red Cross and Red Crescent Societies 2011 (https://reliefweb.int/sites/reliefweb.int/files/resources/MDRCF009finrep.pdf) and 2016 (https://reliefweb.int/report/central-african-republic/central-africa-republic-cholera-epidemic-outbreak-dref-operation).
‡Nomenclature according to Weill et al. (3) (Table 2).
§R1, resistance to polymyxin B and colistin; R2, resistance to polymyxin B, colistin, ampicillin, streptomycin, sulfonamides, vibriostatic agent, trimethoprim/sulfamethoxazole, chloramphenicol; R3, resistance to polymyxin B, colistin, streptomycin, sulfonamides, vibriostatic agent, trimethoprim/sulfamethoxazole, furazolidone, and resistance or intermediate resistance to chloramphenicol.
¶Isolate (CNRVC970079) with the R2 AMR type.

Main Article

References
  1. Barua  DWBG, editor. Cholera. New York: Plenum; 1992.
  2. Lessler  J, Moore  SM, Luquero  FJ, McKay  HS, Grais  R, Henkens  M, et al. Mapping the burden of cholera in sub-Saharan Africa and implications for control: an analysis of data across geographical scales. Lancet. 2018;391:1908–15. DOIPubMedGoogle Scholar
  3. Weill  FX, Domman  D, Njamkepo  E, Tarr  C, Rauzier  J, Fawal  N, et al. Genomic history of the seventh pandemic of cholera in Africa. Science. 2017;358:785–9. DOIPubMedGoogle Scholar
  4. Germani  Y, Quilici  ML, Glaziou  P, Mattera  D, Morvan  J, Fournier  JM. Emergence of cholera in the Central African Republic. Eur J Clin Microbiol Infect Dis. 1998;17:888–90. DOIPubMedGoogle Scholar
  5. Abubakar  A, Bwire  G, Azman  AS, Bouhenia  M, Deng  LL, Wamala  JF, et al. Cholera epidemic in south Sudan and Uganda and need for international collaboration in cholera control. Emerg Infect Dis. 2018;24:883–7. DOIPubMedGoogle Scholar
  6. Weill  FX, Domman  D, Njamkepo  E, Almesbahi  AA, Naji  M, Nasher  SS, et al. Genomic insights into the 2016-2017 cholera epidemic in Yemen. Nature. 2019;565:230–3. DOIPubMedGoogle Scholar
  7. Irenge  LM, Ambroise  J, Mitangala  PN, Bearzatto  B, Kabangwa  RKS, Durant  JF, et al. Genomic analysis of pathogenic isolates of Vibrio cholerae from eastern Democratic Republic of the Congo (2014-2017). PLoS Negl Trop Dis. 2020;14:e0007642. DOIPubMedGoogle Scholar
  8. Bankevich  A, Nurk  S, Antipov  D, Gurevich  AA, Dvorkin  M, Kulikov  AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77. DOIPubMedGoogle Scholar
  9. Larsen  MV, Cosentino  S, Rasmussen  S, Friis  C, Hasman  H, Marvig  RL, et al. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol. 2012;50:1355–61. DOIPubMedGoogle Scholar
  10. Croucher  NJ, Page  AJ, Connor  TR, Delaney  AJ, Keane  JA, Bentley  SD, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res. 2015;43:e15. DOIPubMedGoogle Scholar
  11. Stamatakis  A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics. 2006;22:2688–90. DOIPubMedGoogle Scholar
  12. Domman  D, Quilici  ML, Dorman  MJ, Njamkepo  E, Mutreja  A, Mather  AE, et al. Integrated view of Vibrio cholerae in the Americas. Science. 2017;358:789–93. DOIPubMedGoogle Scholar
  13. Mutreja  A, Kim  DW, Thomson  NR, Connor  TR, Lee  JH, Kariuki  S, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature. 2011;477:462–5. DOIPubMedGoogle Scholar
  14. Ingelbeen  B, Hendrickx  D, Miwanda  B, van der Sande  MAB, Mossoko  M, Vochten  H, et al. Recurrent cholera outbreaks, Democratic Republic of the Congo, 2008–2017. Emerg Infect Dis. 2019;25:856–64. DOIPubMedGoogle Scholar
  15. Penguele  A, Djeintote  M, Balekouzou  A, Tembeti  J, Feilema  P, Kazambu  D, et al. Cholera outbreak investigation in the Central African Republic, October–November 2011 [cited 2020 Feb 23]. https://www.cdcfoundation.org/sites/default/files/upload/pdf/2011CholeraOutbreakReport.pdf

Main Article

1These first authors contributed equally to this article.

2Deceased.

3These authors were joint principal investigators.

Page created: December 01, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external